Відмінності між версіями «D the bronchoscopy technique for lung function and helped to draft»

Версія за 07:38, 15 січня 2018

2013;49(two):167?9. doi:ten.1165/rcmb.2013-0094TR. 5. Chaudhary N, Schnapp A, Park J. Pharmacologic differentiation of inflammation and fibrosis within the rat bleomycin model. Am J Respir Crit Care Med. 2006;173(7):769?6. doi:10.1164/rccm.200505-717OC. six. Izbicki G, Segel M, Christensen T, Conner M, Breuer R. Time course of bleomycin-induced lung fibrosis. Int J Exp Pathol. 2002;83(three):111?. doi:ten.1046/j.1365-2613.2002.00220.x. 7. Peng R, Sridhar S, Tyagi G, Phillips JE, Garrido R, Harris P, et al. Bleomycin induces molecular changes directly relevant to idiopathic pulmonary fibrosis: a model for "active" disease. PLoS One. 2013;8(four):e59348. doi:ten.1371/journal.pone.0059348. eight. Borzone G, Moreno R, Urrea R, Meneses M, Oyarz M, Lisboa C. Bleomycin-induced chronic lung damage will not BML-275 dihydrochloride resemble human idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2001;163(7): 1648?three. doi:ten.1164/ajrccm.163.7.2006132. 9. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M. The bleomycin animal model: a useful tool to investigate treatment title= jir.2011.0103 solutions for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol. 2008;40(3):362?two. doi:ten.1016/j.biocel.2007.08.011. 10. Scotton C, Hayes B, Alexander R, Datta A, Forty E, Mercer P, et al. Ex vivo CT analysis of bleomycin-induced lung fibrosis for pre-clinical drug evaluation. Eur Respir J. 2013. doi:ten.1183/09031936.00182412. 11. Degryse A, Tanjore H, Xu X, Polosukhin V, Jones B, McMahon F, et al. Repetitive intratracheal bleomycin models numerous features of idiopathic pulmonary fibrosis.D the bronchoscopy method for lung function and helped to draft the manuscript. All authors study and approved the final manuscript. Acknowledgements We thank Robin Geyer for help with animal management, handling and tissue collection in the end from the animal experiments. None of your authors had certain funding for this study. C. Samuel is supported by a National Overall health Health-related Analysis Council (NHMRC) of Australia Senior Investigation Fellowship (APP1041766). Chrishan Samuel is supported by a National Wellness Healthcare Analysis Council (NHMRC) of Australia Senior Research Fellowship (APP1041766). Author particulars 1 Faculty of Veterinary and Agricultural Science, The University of Melbourne, Parkville, VIC, Australia. 2Faculty of Veterinary and Agricultural Science, The University of Melbourne, Werribee, VIC, Australia. 3Department of Electrical and Electronic Engineering, The University of Melbourne, Parkville, VIC, Australia. 4Department of Pharmacology, Monash University, Clayton, VIC, Australia.Organ et al. BMC Pulmonary Medicine (2015) 15:Page title= fnhum.2014.00074 14 ofReceived: eight April 2015 Accepted: six JulyReferences 1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based suggestions for diagnosis and management. Am J Respir Crit Care Med. 2011;183(six):788?24. doi:10.1164/rccm.2009-040GL. 2. Jr TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in sufferers with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083?two. three. Richeldi L, du RM, Raghu G. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. .... J Med. 2014;370(22):2071?two.